Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZB716 |
Synonyms | |
Therapy Description |
ZB716 is a selective estrogen receptor degrader (SERD) that may inhibit growth of ESR1 (ER alpha)-positive tumor cells and decrease tumor growth (PMID: 29467940). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZB716 | ZB 716|ZB-716|Borestrant | Hormone - Anti-estrogens 29 | ZB716 is a selective estrogen receptor degrader (SERD) that may inhibit growth of ESR1 (ER alpha)-positive tumor cells and decrease tumor growth (PMID: 29467940). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04669587 | Phase Ib/II | ZB716 Palbociclib + ZB716 | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (ENZENO) | Unknown status | USA | 1 |